VK-2019
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Carcinoma
Conditions
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Trial Timeline
Apr 4, 2019 → Aug 8, 2020
NCT ID
NCT03682055About VK-2019
VK-2019 is a phase 1/2 stage product being developed by Cullinan Therapeutics for Nasopharyngeal Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03682055. Target conditions include Nasopharyngeal Carcinoma, Nasopharyngeal Cancer.
What happened to similar drugs?
0 of 13 similar drugs in Nasopharyngeal Carcinoma were approved
Approved (0) Terminated (0) Active (13)
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
9
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03682055 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Nasopharyngeal Carcinoma